Ozempic, originally approved for type 2 diabetes management, has received FDA approval to mitigate risks associated with chronic kidney disease. A Phase 3 clinical trial revealed that this medication significantly reduced kidney disease progression by 24% and lowered the risk of kidney failure and heart-related deaths in diabetic patients. As chronic kidney disease commonly affects diabetic individuals, this approval positions Ozempic as a versatile treatment choice. The drug now boasts the most extensive indications among its class, though further studies are needed to clarify the mechanisms behind its positive effects.
The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set of specific medical conditions that it may be prescribed to treat.
A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% among those with diabetes.
Collection
[
|
...
]